DDInter195 DDInter1376
Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Betamethasone {u} (Compound) resembles {v} (Compound) Mometasone
Betamethasone {u} (Compound) resembles {v} (Compound) Fludrocortisone
Betamethasone {u} (Compound) treats {v} (Disease) allergic rhinitis
Betamethasone {u} (Compound) binds {v} (Gene) CYP3A4
Betamethasone {u} (Compound) upregulates {v} (Gene) GSPT1
Betamethasone {u} (Compound) palliates {v} (Disease) kidney cancer
Betamethasone {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Betamethasone {u} (Compound) downregulates {v} (Gene) DDIT3
Betamethasone {u} (Compound) causes {v} (Side Effect) Blindness
Betamethasone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Orciprenaline
Betamethasone (Compound) resembles Mometasone (Compound)
Betamethasone (Compound) resembles Fludrocortisone (Compound)
Betamethasone (Compound) treats allergic rhinitis (Disease)
Betamethasone (Compound) binds CYP3A4 (Gene)
Betamethasone (Compound) upregulates GSPT1 (Gene)
Betamethasone (Compound) palliates kidney cancer (Disease)
Betamethasone (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Betamethasone (Compound) downregulates DDIT3 (Gene)
Betamethasone (Compound) causes Blindness (Side Effect)
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline